
    
      The study objectives of this study are to determine the effects, safety, and pharmacokinetics
      of bendamustine for untreated and maladjustment to hematopoietic stem cell transplantation
      (HSCT) multiple myeloma to a regimen of bendamustine and prednisolone.
    
  